{"transactions":[{"id":730428,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:14:57.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders."}],"balance_after":2340,"derivative":{"exercise_price":2.02,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":2340},"source":{"system":"sec-edgar","filing":"0000905148-26-003043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000090514826003043/form4.xml","form_type":"4"}},{"id":731934,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:00:18.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":25319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":25319,"derivative":{"exercise_price":13.55,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":25319},"source":{"system":"sec-edgar","filing":"0001193125-26-276057","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000119312526276057/ownership.xml","form_type":"4"}},{"id":743629,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:59.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":13587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":13587,"derivative":{"exercise_price":11,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13587},"source":{"system":"sec-edgar","filing":"0001193125-26-266279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266279/ownership.xml","form_type":"4"}},{"id":1102584,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T20:30:40.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":18700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders."}],"balance_after":18700,"derivative":{"exercise_price":0.47,"expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":18700},"source":{"system":"sec-edgar","filing":"0000905148-25-002242","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000090514825002242/form4.xml","form_type":"4"}},{"id":1109699,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:10:34.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":38513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date"}],"balance_after":38513,"derivative":{"exercise_price":8.95,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":38513},"source":{"system":"sec-edgar","filing":"0000950170-25-086726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000095017025086726/ownership.xml","form_type":"4"}},{"id":1175395,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-09T00:54:21.000Z","date":"2025-04-04","kind":"other","planned":false,"acquired":false,"shares":7379,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.76,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":7379},"source":{"system":"sec-edgar","filing":"0001415889-25-010435","document":"form4-04092025_120417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000141588925010435/form4-04092025_120417.xml","form_type":"4"}},{"id":1175394,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-09T00:54:21.000Z","date":"2025-04-04","kind":"other","planned":false,"acquired":false,"shares":103600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 1/36th of the total grant monthly beginning May 26, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.81,"expiration_date":"2034-04-25","underlying":"Common Stock","underlying_shares":103600},"source":{"system":"sec-edgar","filing":"0001415889-25-010435","document":"form4-04092025_120417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000141588925010435/form4-04092025_120417.xml","form_type":"4"}},{"id":1175393,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-09T00:54:21.000Z","date":"2025-04-04","kind":"other","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's Second Modified Plan of Reorganization pursuant to Chapter 11 of the Bankruptcy Code, which was confirmed by the United States Bankruptcy Court for the District of Delaware on April 3, 2025 and became effective on April 4, 2025, each share of the Issuer's common stock and options to purchase the Issuer's common stock outstanding prior to the Issuer's emergence from bankruptcy were cancelled for no value."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-010435","document":"form4-04092025_120417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000141588925010435/form4-04092025_120417.xml","form_type":"4"}},{"id":1468048,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-27T23:00:06.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":15806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 15,806 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 26, 2025 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":15806,"derivative":{"exercise_price":16.5,"expiration_date":"2034-06-26","underlying":"Common Stock","underlying_shares":15806},"source":{"system":"sec-edgar","filing":"0000950170-24-078678","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000095017024078678/ownership.xml","form_type":"4"}},{"id":1471943,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T21:05:08.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":18700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders."}],"balance_after":18700,"derivative":{"exercise_price":1.5,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":18700},"source":{"system":"sec-edgar","filing":"0000905148-24-001769","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000090514824001769/form4.xml","form_type":"4"}},{"id":1473054,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T21:58:53.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":7379,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date."}],"balance_after":7379,"derivative":{"exercise_price":0.76,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":7379},"source":{"system":"sec-edgar","filing":"0001415889-24-017705","document":"form4-06202024_090649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000141588924017705/form4-06202024_090649.xml","form_type":"4"}},{"id":1532814,"issuer":{"id":80946,"kind":"organization","name":"Gritstone bio, Inc.","symbol":"GRTS"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-30T22:28:27.000Z","date":"2024-04-26","kind":"grant","planned":false,"acquired":true,"shares":103600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36th of the total grant monthly beginning May 26, 2024 until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date."}],"balance_after":103600,"derivative":{"exercise_price":0.81,"expiration_date":"2034-04-25","underlying":"Common Stock","underlying_shares":103600},"source":{"system":"sec-edgar","filing":"0001415889-24-011805","document":"form4-04302024_100421.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000141588924011805/form4-04302024_100421.xml","form_type":"4"}},{"id":1845087,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T20:30:45.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":1.62,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001140361-23-031188","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000114036123031188/form4.xml","form_type":"4"}},{"id":1858662,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T21:51:30.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 18,450 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 8, 2024 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":18450,"derivative":{"exercise_price":13,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18450},"source":{"system":"sec-edgar","filing":"0000950170-23-027538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000095017023027538/ownership.xml","form_type":"4"}},{"id":1872131,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:25:00.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":9.54,"underlying":"Common Stock","underlying_shares":10482},"source":{"system":"sec-edgar","filing":"0001104659-23-067057","document":"tm2317472-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067057/tm2317472-7_4seq1.xml","form_type":"4"}},{"id":1872130,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:25:00.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":5.21,"underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001104659-23-067057","document":"tm2317472-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067057/tm2317472-7_4seq1.xml","form_type":"4"}},{"id":1872129,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:25:00.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":31.83,"underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001104659-23-067057","document":"tm2317472-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067057/tm2317472-7_4seq1.xml","form_type":"4"}},{"id":1872128,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-01T16:25:00.000Z","date":"2023-06-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the \"Company\"), Adaptimmune Therapeutics plc (\"Parent\") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the \"Merger Agreement\"), pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Company (each, a \"Share\") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the \"Exchange Ratio\") American Depositary Shares of Parent (\"Parent ADS\") representing six ordinary shares of Parent (\"Parent Ordinary Shares\"). Immediately prior to the Effective Time, each option to acquire Shares (each, a \"Company Option\") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs."}],"balance_after":0,"derivative":{"exercise_price":0.97,"underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0001104659-23-067057","document":"tm2317472-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000110465923067057/tm2317472-7_4seq1.xml","form_type":"4"}},{"id":2081778,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-19T17:06:25.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":16800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter."}],"balance_after":16800,"derivative":{"exercise_price":0.97,"expiration_date":"2032-12-14","underlying":"Common Stock","underlying_shares":16800},"source":{"system":"sec-edgar","filing":"0000899243-22-039006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924322039006/doc4.xml","form_type":"4"}},{"id":2194401,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-04T22:20:55.000Z","date":"2022-08-02","kind":"sale","acquired":false,"shares":7826,"price":0.19,"value":1486.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":11447,"source":{"system":"sec-edgar","filing":"0001104659-22-086279","document":"tm2222534-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465922086279/tm2222534-11_4seq1.xml","form_type":"4"}},{"id":2221972,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T21:28:13.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":4.77,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001567619-22-013369","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000156761922013369/doc1.xml","form_type":"4"}},{"id":2222977,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-23T22:18:11.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":16475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":16475,"derivative":{"exercise_price":12.73,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":16475},"source":{"system":"sec-edgar","filing":"0000899243-22-023769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924322023769/doc4.xml","form_type":"4"}},{"id":2317637,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-25T23:33:28.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":7800,"derivative":{"exercise_price":28.8,"expiration_date":"2031-09-15","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0000899243-22-012376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924322012376/doc4.xml","form_type":"4"}},{"id":2477340,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T16:36:15.000Z","date":"2021-12-09","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in twenty-four (24) equal monthly installments thereafter."}],"balance_after":12100,"derivative":{"exercise_price":5.21,"expiration_date":"2031-12-08","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001209191-21-069061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919121069061/doc4.xml","form_type":"4"}},{"id":2614719,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-08-05T01:08:16.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":777,"price":1.2,"value":932.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.205, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19273,"source":{"system":"sec-edgar","filing":"0001104659-21-100291","document":"tm2123911-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465921100291/tm2123911-8_4seq1.xml","form_type":"4"}},{"id":2621144,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-07-31T00:19:32.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option was granted on July 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":1.08,"expiration_date":"2031-07-27","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-21-098424","document":"tm2123737-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465921098424/tm2123737-4_4seq1.xml","form_type":"4"}},{"id":2621143,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-31T00:19:32.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020."}],"balance_after":20050,"source":{"system":"sec-edgar","filing":"0001104659-21-098424","document":"tm2123737-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465921098424/tm2123737-4_4seq1.xml","form_type":"4"}},{"id":2653350,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T22:10:52.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":8.21,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001567619-21-012667","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000156761921012667/doc1.xml","form_type":"4"}},{"id":2948781,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-11T06:22:53.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":12100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on January 1, 2022, with the remainder vesting in twenty-four (24) equal monthly installments thereafter."}],"balance_after":12100,"derivative":{"exercise_price":31.83,"expiration_date":"2030-12-09","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0000899243-20-033481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924320033481/doc4.xml","form_type":"4"}},{"id":3072459,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-07-31T20:55:50.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The option was granted on July 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the option will vest on July 31, 2021, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":0.79,"expiration_date":"2030-07-28","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-20-089143","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465920089143/a4.xml","form_type":"4"}},{"id":3072458,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-07-31T20:55:50.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0001104659-20-089143","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465920089143/a4.xml","form_type":"4"}},{"id":3110460,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T21:46:28.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":24.13,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001123292-20-000884","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000112329220000884/edgar.xml","form_type":"4"}},{"id":3163802,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-04T17:11:26.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":10482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on April 30, 2021, with the remainder vesting in thirty-six (36) equal monthly installments thereafter."}],"balance_after":10482,"derivative":{"exercise_price":9.54,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":10482},"source":{"system":"sec-edgar","filing":"0001209191-20-026858","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000120919120026858/doc4.xml","form_type":"4"}},{"id":3322753,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-04T01:01:06.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":7.95,"exercise_date":"2021-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-001425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000120919120001425/doc4.xml","form_type":"4"}},{"id":3338714,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings)."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338713,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":106015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":106015},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338712,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":68.45,"expiration_date":"2025-03-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338711,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":40.44,"expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338710,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":56.17,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338709,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":50.55,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338708,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"disposition_to_issuer","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option."}],"balance_after":0,"derivative":{"exercise_price":42.73,"expiration_date":"2029-01-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3338707,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2019-12-17T21:53:04.000Z","date":"2019-12-17","kind":"other","acquired":false,"shares":6102,"price":114.5,"value":698679.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. (\"Spark\"), Roche Holdings, Inc. (\"Roche\") and 022019 Merger Subsidiary, Inc. (\"Merger Sub\") (the \"Merger Agreement\" and the transactions contemplated thereby, the \"Merger\"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-029449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000089924319029449/doc4.xml","form_type":"4"}},{"id":3450801,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-08-01T20:15:49.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $2.38 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"expiration_date":"2029-07-31","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-19-043340","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465919043340/a4.xml","form_type":"4"}},{"id":3487636,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-18T00:20:40.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on June 13, 2020."}],"balance_after":22000,"derivative":{"exercise_price":15.57,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001123292-19-000887","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000112329219000887/edgar.xml","form_type":"4"}},{"id":3689304,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-23T22:17:24.000Z","date":"2019-01-18","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 18, 2018, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019.  Vested shares will be delivered to the reporting person annually on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 18, 2018, the reporting person was granted 8,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019.  Vested shares will be delivered to the reporting person annually on the vesting date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001609351-19-000028","document":"wf-form4_154828182777430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000028/wf-form4_154828182777430.xml","form_type":"4"}},{"id":3689303,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-23T22:17:24.000Z","date":"2019-01-18","kind":"exercise","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date."}],"balance_after":3500,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001609351-19-000028","document":"wf-form4_154828182777430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000028/wf-form4_154828182777430.xml","form_type":"4"}},{"id":3689302,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-23T22:17:24.000Z","date":"2019-01-18","kind":"tax_withholding","acquired":false,"shares":629,"price":45.08,"value":28355.32,"ownership":{"direct":true},"balance_after":6102,"source":{"system":"sec-edgar","filing":"0001609351-19-000028","document":"wf-form4_154828182777430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000028/wf-form4_154828182777430.xml","form_type":"4"}},{"id":3689301,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-23T22:17:24.000Z","date":"2019-01-18","kind":"exercise","acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock."}],"balance_after":6731,"source":{"system":"sec-edgar","filing":"0001609351-19-000028","document":"wf-form4_154828182777430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000028/wf-form4_154828182777430.xml","form_type":"4"}},{"id":3689300,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-23T22:17:24.000Z","date":"2019-01-18","kind":"tax_withholding","acquired":false,"shares":634,"price":45.08,"value":28580.72,"ownership":{"direct":true},"balance_after":4731,"source":{"system":"sec-edgar","filing":"0001609351-19-000028","document":"wf-form4_154828182777430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000028/wf-form4_154828182777430.xml","form_type":"4"}},{"id":3689299,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-01-23T22:17:24.000Z","date":"2019-01-18","kind":"exercise","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock."}],"balance_after":5365,"source":{"system":"sec-edgar","filing":"0001609351-19-000028","document":"wf-form4_154828182777430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000028/wf-form4_154828182777430.xml","form_type":"4"}},{"id":3692915,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-18T02:44:36.000Z","date":"2019-01-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 15, 2020.  Vested shares will be delivered to the reporting person annually on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 15, 2020.  Vested shares will be delivered to the reporting person annually on the vesting date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001609351-19-000013","document":"wf-form4_154777945875515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000013/wf-form4_154777945875515.xml","form_type":"4"}},{"id":3692914,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-18T02:44:36.000Z","date":"2019-01-15","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years."}],"balance_after":35000,"derivative":{"exercise_price":42.73,"expiration_date":"2029-01-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001609351-19-000013","document":"wf-form4_154777945875515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935119000013/wf-form4_154777945875515.xml","form_type":"4"}},{"id":3708557,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T01:28:54.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":8.32,"exercise_date":"2020-01-02","expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-19-001566","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000120919119001566/doc4.xml","form_type":"4"}},{"id":3912380,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2018-05-31T22:59:42.000Z","date":"2018-05-29","kind":"purchase","acquired":true,"shares":8000,"price":5.214,"value":41712.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.203 to $5.216, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-18-034485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000120919118034485/doc4.xml","form_type":"4"}},{"id":3920424,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-24T00:37:25.000Z","date":"2018-05-23","kind":"purchase","acquired":true,"shares":8000,"price":4.59,"value":36720.0,"ownership":{"direct":true},"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001104659-18-035538","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465918035538/a4.xml","form_type":"4"}},{"id":3945522,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-05-04T20:01:57.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $4.91 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019."}],"balance_after":29000,"derivative":{"expiration_date":"2028-05-02","underlying":"Ordinary Shares","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001104659-18-030623","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465918030623/a4.xml","form_type":"4"}},{"id":4093613,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-23T00:05:39.000Z","date":"2018-01-18","kind":"exercise","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 18, 2017, the reporting person was granted 7,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date."}],"balance_after":5250,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001609351-18-000015","document":"wf-form4_151666592504230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935118000015/wf-form4_151666592504230.xml","form_type":"4"}},{"id":4093612,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-23T00:05:39.000Z","date":"2018-01-18","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning January 18, 2019.  Vested shares will be delivered to the reporting person annually on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest in four equal annual installments beginning January 18, 2019.  Vested shares will be delivered to the reporting person annually on the vesting date."}],"balance_after":8000,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001609351-18-000015","document":"wf-form4_151666592504230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935118000015/wf-form4_151666592504230.xml","form_type":"4"}},{"id":4093611,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-23T00:05:39.000Z","date":"2018-01-18","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% vests January 18, 2019 and the remainder vests in equal annual installments over the following three years."}],"balance_after":28000,"derivative":{"exercise_price":50.55,"expiration_date":"2028-01-17","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001609351-18-000015","document":"wf-form4_151666592504230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935118000015/wf-form4_151666592504230.xml","form_type":"4"}},{"id":4093610,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-23T00:05:39.000Z","date":"2018-01-18","kind":"tax_withholding","acquired":false,"shares":635,"price":50.55,"value":32099.25,"ownership":{"direct":true},"balance_after":3615,"source":{"system":"sec-edgar","filing":"0001609351-18-000015","document":"wf-form4_151666592504230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935118000015/wf-form4_151666592504230.xml","form_type":"4"}},{"id":4093609,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-01-23T00:05:39.000Z","date":"2018-01-18","kind":"exercise","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit converted into one share of Spark Therapeutics common stock."}],"balance_after":4250,"source":{"system":"sec-edgar","filing":"0001609351-18-000015","document":"wf-form4_151666592504230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935118000015/wf-form4_151666592504230.xml","form_type":"4"}},{"id":4111598,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-03T21:18:14.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":4.48,"exercise_date":"2019-01-02","expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-18-000858","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000120919118000858/doc4.xml","form_type":"4"}},{"id":4156220,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-11-20T22:14:58.000Z","date":"2017-11-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter."}],"balance_after":106015,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001609351-17-000120","document":"wf-form4_151121608406993.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000120/wf-form4_151121608406993.xml","form_type":"4"}},{"id":4156219,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-11-20T22:14:58.000Z","date":"2017-11-16","kind":"sale","acquired":false,"shares":10000,"price":70.14,"value":701400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $70.00 to $70.95, inclusive.  The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001609351-17-000120","document":"wf-form4_151121608406993.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000120/wf-form4_151121608406993.xml","form_type":"4"}},{"id":4156218,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-11-20T22:14:58.000Z","date":"2017-11-16","kind":"exercise","acquired":true,"shares":10000,"price":3.45,"value":34500.0,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001609351-17-000120","document":"wf-form4_151121608406993.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000120/wf-form4_151121608406993.xml","form_type":"4"}},{"id":4205637,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-09-20T01:31:07.000Z","date":"2017-09-15","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $6.86 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018."}],"balance_after":10100,"derivative":{"expiration_date":"2027-09-15","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-057952","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465917057952/a4.xml","form_type":"4"}},{"id":4233849,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-08-15T21:05:17.000Z","date":"2017-08-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter."}],"balance_after":116015,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001609351-17-000094","document":"wf-form4_150283110362981.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000094/wf-form4_150283110362981.xml","form_type":"4"}},{"id":4233848,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-15T21:05:17.000Z","date":"2017-08-15","kind":"sale","acquired":false,"shares":10000,"price":79.38,"value":793800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $79.20 to $79.67, inclusive.  The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001609351-17-000094","document":"wf-form4_150283110362981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000094/wf-form4_150283110362981.xml","form_type":"4"}},{"id":4233847,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-15T21:05:17.000Z","date":"2017-08-15","kind":"exercise","acquired":true,"shares":10000,"price":3.45,"value":34500.0,"ownership":{"direct":true},"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001609351-17-000094","document":"wf-form4_150283110362981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000094/wf-form4_150283110362981.xml","form_type":"4"}},{"id":4245588,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-08-02T21:58:23.000Z","date":"2017-07-31","kind":"exercise","acquired":false,"shares":2337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter."}],"balance_after":126015,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":2337},"source":{"system":"sec-edgar","filing":"0001609351-17-000088","document":"wf-form4_150171109013600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000088/wf-form4_150171109013600.xml","form_type":"4"}},{"id":4245587,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-02T21:58:23.000Z","date":"2017-07-31","kind":"sale","acquired":false,"shares":2337,"price":71.12,"value":166207.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017, as amended."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001609351-17-000088","document":"wf-form4_150171109013600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000088/wf-form4_150171109013600.xml","form_type":"4"}},{"id":4245586,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-08-02T21:58:23.000Z","date":"2017-07-31","kind":"exercise","acquired":true,"shares":2337,"price":3.45,"value":8062.65,"ownership":{"direct":true},"balance_after":4837,"source":{"system":"sec-edgar","filing":"0001609351-17-000088","document":"wf-form4_150171109013600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000088/wf-form4_150171109013600.xml","form_type":"4"}},{"id":4271695,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-28T01:56:51.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017."}],"balance_after":10100,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-041907","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465917041907/a4.xml","form_type":"4"}},{"id":4271694,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-28T01:56:51.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":20200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016."}],"balance_after":20200,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":20200},"source":{"system":"sec-edgar","filing":"0001104659-17-041907","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000110465917041907/a4.xml","form_type":"4"}},{"id":4275250,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-21T20:43:51.000Z","date":"2017-06-19","kind":"exercise","acquired":false,"shares":7663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter."}],"balance_after":128352,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":7663},"source":{"system":"sec-edgar","filing":"0001609351-17-000060","document":"wf-form4_149807781707901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000060/wf-form4_149807781707901.xml","form_type":"4"}},{"id":4275249,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-21T20:43:51.000Z","date":"2017-06-19","kind":"sale","acquired":false,"shares":7663,"price":60,"value":459780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2017."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001609351-17-000060","document":"wf-form4_149807781707901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000060/wf-form4_149807781707901.xml","form_type":"4"}},{"id":4275248,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-21T20:43:51.000Z","date":"2017-06-19","kind":"exercise","acquired":true,"shares":7663,"price":3.45,"value":26437.35,"ownership":{"direct":true},"balance_after":10163,"source":{"system":"sec-edgar","filing":"0001609351-17-000060","document":"wf-form4_149807781707901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000060/wf-form4_149807781707901.xml","form_type":"4"}},{"id":4344540,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-04-26T21:48:07.000Z","date":"2017-04-25","kind":"exercise","acquired":false,"shares":8102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter."}],"balance_after":136015,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":8102},"source":{"system":"sec-edgar","filing":"0001609351-17-000028","document":"wf-form4_149324327094392.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000028/wf-form4_149324327094392.xml","form_type":"4"}},{"id":4344539,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-04-26T21:48:07.000Z","date":"2017-04-24","kind":"exercise","acquired":false,"shares":1898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on July 7, 2014 and vests over four years, with 25% of the shares underlying the option vesting on July 7, 2015, and the remainder vesting quarterly thereafter."}],"balance_after":144117,"derivative":{"exercise_price":3.45,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":1898},"source":{"system":"sec-edgar","filing":"0001609351-17-000028","document":"wf-form4_149324327094392.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000028/wf-form4_149324327094392.xml","form_type":"4"}},{"id":4344538,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-26T21:48:07.000Z","date":"2017-04-25","kind":"sale","acquired":false,"shares":8102,"price":55.22,"value":447392.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27,2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $55.00 to $55.67, inclusive.  The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001609351-17-000028","document":"wf-form4_149324327094392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000028/wf-form4_149324327094392.xml","form_type":"4"}},{"id":4344537,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-26T21:48:07.000Z","date":"2017-04-25","kind":"exercise","acquired":true,"shares":8102,"price":3.45,"value":27951.9,"ownership":{"direct":true},"balance_after":10602,"source":{"system":"sec-edgar","filing":"0001609351-17-000028","document":"wf-form4_149324327094392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000028/wf-form4_149324327094392.xml","form_type":"4"}},{"id":4344536,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-26T21:48:07.000Z","date":"2017-04-24","kind":"sale","acquired":false,"shares":1898,"price":55,"value":104390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27,2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $55.00 to $55.02, inclusive.  The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001609351-17-000028","document":"wf-form4_149324327094392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000028/wf-form4_149324327094392.xml","form_type":"4"}},{"id":4344535,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-26T21:48:07.000Z","date":"2017-04-24","kind":"exercise","acquired":true,"shares":1898,"price":3.45,"value":6548.1,"ownership":{"direct":true},"balance_after":4398,"source":{"system":"sec-edgar","filing":"0001609351-17-000028","document":"wf-form4_149324327094392.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000028/wf-form4_149324327094392.xml","form_type":"4"}},{"id":4485215,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-01-20T21:04:49.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 18, 2018.  Vested shares will be delivered to the reporting person annually on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning January 18, 2018.  Vested shares will be delivered to the reporting person annually on the vesting date."}],"balance_after":7000,"derivative":{"underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001609351-17-000008","document":"wf-form4_148494627552283.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000008/wf-form4_148494627552283.xml","form_type":"4"}},{"id":4485214,"issuer":{"id":153045,"kind":"organization","name":"Spark Therapeutics, Inc.","symbol":"ONCE"},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-01-20T21:04:49.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years."}],"balance_after":25000,"derivative":{"exercise_price":56.17,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001609351-17-000008","document":"wf-form4_148494627552283.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000160935117000008/wf-form4_148494627552283.xml","form_type":"4"}},{"id":4498415,"issuer":{"id":4067,"kind":"organization","name":"Viking Therapeutics, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-06T00:16:49.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":1.19,"exercise_date":"2018-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-17-002382","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438421/000120919117002382/doc4.xml","form_type":"4"}}]}